Did you ever watch deal or no deal? Bocx like other emerging biotechs has a constant need for cash to continue. They need ABT to provide it or enter into other agreements or borrowing with its dillution. Products developed but not in the market place produce no revenue. Bocx needs a source of cash. Until they get it the stock price will remain low.
Your post says there are 975 shares short, that would be part of one trade. Frequently in stocks like this the short postition is created because the selling market maker is late delivering the stock. Under the new rules the shares that aren't delivered on time are short. The short interest in this stock is inconsequential at this time.
News 
Market Data 
Discover 
